Last reviewed · How we verify
rabeprazole-based triple therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
rabeprazole-based triple therapy (rabeprazole-based triple therapy) — Kaohsiung Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| rabeprazole-based triple therapy TARGET | rabeprazole-based triple therapy | Kaohsiung Medical University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- rabeprazole-based triple therapy CI watch — RSS
- rabeprazole-based triple therapy CI watch — Atom
- rabeprazole-based triple therapy CI watch — JSON
- rabeprazole-based triple therapy alone — RSS
Cite this brief
Drug Landscape (2026). rabeprazole-based triple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/rabeprazole-based-triple-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing